A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of loading doses of intravenous
Bondronat in patients with breast cancer and malignant bone disease experiencing moderate to
severe bone pain. Patients will receive an intravenous infusion of 6mg Bondronat on days 1, 2
and 3. The anticipated time on study treatment is 3 months, and the target sample size is
<100 individuals.